NDAORALTABLET, EXTENDED RELEASEPriority Review
Approved
Jan 2010
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
5/8 — Partial
Priority Review
AMPYRA (dalfampridine) by Merz Therapeutics is potassium channel antagonists [moa]. First approved in 2010.
Drug data last refreshed 12h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AMPYRA (dalfampridine) is an oral potassium channel antagonist approved in 2010 for multiple sclerosis. It works by blocking potassium channels, which enhances action potential propagation in demyelinated axons. The drug is indicated to improve walking speed in MS patients.
$44MPart D
LOE ApproachingDeclining
With LOE approaching and modest Part D spending of $44M, the commercial team is likely contracting and focused on defensive market maintenance rather than expansion.
Mechanism of Action
Potassium Channel Antagonists
Pharmacologic Class:
Potassium Channel Blocker
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
FAME - Fampyra Outcome Measures Study: a Study of Different Outcome Measures on the Effect of Fampyra
Started Jun 2012
108 enrolled
Multiple Sclerosis
An Observational Study to Collect Information on Safety and to Document the Drug Utilization of Fampyra (BIIB041) When Used In Routine Medical Practice
Started Apr 2012
4,734 enrolled
Multiple Sclerosis
Dalfampridine for Imbalance in Multiple Sclerosis
Started Sep 2011
24 enrolled
Multiple SclerosisFatigue
Career Relevance
The linked job portfolio for AMPYRA is minimal (3 positions) and heavily weighted toward corporate functions (HR, social media) rather than core pharma roles. This reflects the product's mature, stable lifecycle and Merz's likely consolidation of commercial headcount as LOE approaches.
Worked on AMPYRA at Merz Therapeutics? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.